基蛋生物
(603387)
| 流通市值：39.96亿 | | | 总市值：39.96亿 |
| 流通股本：5.07亿 | | | 总股本：5.07亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 244,148,446.89 | 1,164,798,937.4 | 879,824,587.76 | 617,667,779.49 |
| 营业收入 | 244,148,446.89 | 1,164,798,937.4 | 879,824,587.76 | 617,667,779.49 |
| 二、营业总成本 | 168,580,188.57 | 890,272,619.92 | 676,679,065.46 | 466,817,209.47 |
| 营业成本 | 55,795,509.45 | 358,423,981.76 | 268,955,795.91 | 189,887,885.17 |
| 税金及附加 | 2,767,029.47 | 14,385,714.83 | 10,369,616.26 | 7,560,122.86 |
| 销售费用 | 53,122,124.93 | 275,905,069.91 | 211,870,182.7 | 145,456,121.66 |
| 管理费用 | 19,360,207.9 | 95,695,826.75 | 66,311,847.95 | 47,350,933.99 |
| 研发费用 | 43,457,520.56 | 181,207,210.95 | 137,226,238.04 | 92,414,490.91 |
| 财务费用 | -5,922,203.74 | -35,345,184.28 | -18,054,615.4 | -15,852,345.12 |
| 其中:利息费用 | 3,691,297.76 | 14,927,328.85 | 12,103,543.02 | 7,912,186.19 |
| 其中:利息收入 | 9,555,133.11 | 44,957,952.62 | 32,797,829.28 | 21,486,110.61 |
| 加:公允价值变动收益 | 3,089,177.27 | 149,352.07 | 6,504,688.08 | 5,022,669.76 |
| 加:投资收益 | 627,362.08 | 827,109.26 | 3,507,036.6 | 750,663.64 |
| 资产处置收益 | 245,733.19 | 1,594,616.6 | -1,345,758.71 | -1,442,230.82 |
| 资产减值损失(新) | -2,928,918.69 | -41,793,091.25 | -28,845,559.45 | -883,998.09 |
| 信用减值损失(新) | -11,319,758.83 | -13,699,668.24 | -7,884,382.88 | -9,535,842.26 |
| 其他收益 | 3,958,277.9 | 36,447,551.79 | 28,878,683.63 | 21,898,266.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 69,240,131.24 | 258,052,187.71 | 203,960,229.57 | 166,660,098.79 |
| 加:营业外收入 | 337,056.04 | 2,053,267.16 | 1,726,499.58 | 1,083,300.48 |
| 减:营业外支出 | 2,027,008.23 | 6,673,601.36 | 3,160,937 | 1,560,784.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 67,550,179.05 | 253,431,853.51 | 202,525,792.15 | 166,182,614.71 |
| 减:所得税费用 | 5,246,767.81 | 23,553,069.22 | 20,621,255.3 | 15,267,118.53 |
| 六、净利润 | 62,303,411.24 | 229,878,784.29 | 181,904,536.85 | 150,915,496.18 |
| 持续经营净利润 | 62,303,411.24 | 229,878,784.29 | 181,904,536.85 | 150,915,496.18 |
| 归属于母公司股东的净利润 | 64,307,429.35 | 223,636,488.43 | 175,418,840.09 | 146,808,888.87 |
| 少数股东损益 | -2,004,018.11 | 6,242,295.86 | 6,485,696.76 | 4,106,607.31 |
| (一)基本每股收益 | 0.13 | 0.44 | 0.35 | 0.29 |
| (二)稀释每股收益 | 0.13 | 0.44 | 0.35 | 0.29 |
| 八、其他综合收益 | -9,615.09 | 88,199.98 | 7,716,154.45 | 135,059.72 |
| 归属于母公司股东的其他综合收益 | -9,615.09 | 88,199.98 | 5,748,948.97 | 135,059.72 |
| 九、综合收益总额 | 62,293,796.15 | 229,966,984.27 | 189,620,691.3 | 151,050,555.9 |
| 归属于母公司股东的综合收益总额 | 64,297,814.26 | 223,724,688.41 | 181,167,789.06 | 146,943,948.59 |
| 归属于少数股东的综合收益总额 | -2,004,018.11 | 6,242,295.86 | 8,452,902.24 | 4,106,607.31 |
| 公告日期 | 2025-04-30 | 2025-04-30 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 保留意见 | | |